Crinetics Discloses Shareholder Lawsuits and Supplemental Proxy Details Ahead of Vertex Merger Vote
CRNX has more than doubled off its 52-week low of $28.73.
Summary
Crinetics disclosed three shareholder lawsuits challenging its proxy disclosures for the Vertex merger and provided supplemental details on financial analyses and management forecasts ahead of the August 28 shareholder vote.
Key Events · Legal and Risk Events · CRNX
-
Shareholder Lawsuits Filed
Three purported shareholders filed complaints on August 6 and August 17, 2026, alleging the proxy statement contained materially false and misleading statements and omitted material information.
-
Supplemental Disclosures Provided
Crinetics voluntarily supplemented the proxy statement with detailed financial advisor analyses, including J.P. Morgan's implied equity value range of $30.75 to $95.00 per share and Leerink Partners' DCF analysis.
-
Management Forecasts Disclosed
The supplemental disclosures include management forecasts projecting risk-adjusted total revenue growing from $105 million in 2026 to $1,057 million in 2030 and $4,583 million in 2035.
-
Special Meeting Scheduled
The special meeting of shareholders to vote on the merger is scheduled for August 28, 2026, and the board continues to unanimously recommend approval.
Analysis · CRNX · Life Sciences
Three shareholder lawsuits allege the proxy statement for the $10 billion Vertex acquisition contains materially false and misleading statements. Crinetics denies the claims but voluntarily supplemented disclosures with detailed financial advisor analyses and management forecasts. The special meeting to approve the merger is scheduled for August 28, 2026, and these lawsuits could delay or complicate the closing.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRNX was trading at $84.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9B. The 52-week trading range was $28.73 to $84.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.